TRex Bio, a clinical-stage biotechnology company developing treatments for autoimmune and inflammatory diseases, has raised $117 million in its initial public offering, pricing 8.3 million shares at $14 each. The offering priced at the low end of the proposed $14 to $16 range, with Eli Lilly, an existing investor and discovery partner, indicating interest in purchasing $12 million worth of shares, representing approximately 10% of the deal.
IPO Pricing and Nasdaq Listing
TRex Bio priced its IPO at $14 per share, the bottom of its proposed range. The company raised approximately $117 million by offering 8.3 million shares, providing funding to advance its clinical-stage pipeline.
The company will trade on the Nasdaq under the symbol TRXB. J.P. Morgan, Evercore ISI, Cantor Fitzgerald, Stifel and Wedbush Securities acted as joint bookrunners for the offering.
Eli Lilly’s indicated $12 million share purchase represents a notable commitment from an existing investor and partner, although the supplied information does not specify the final allocation of those shares.
Deep Biology Platform Targets Immune Regulation
TRex Bio is developing medicines designed to augment regulatory T cells, or Tregs, in inflamed human tissue. Its approach aims to restore immune balance and repair barrier damage rather than broadly suppressing the immune system.
The company’s Deep Biology platform maps Treg function in fresh human skin, gut and lung tissue to identify potential therapeutic targets. Those targets are then evaluated using a proprietary in vitro Treg model and a high-throughput functional assay suite.
The platform is intended to support the discovery and validation of treatments for autoimmune and inflammatory diseases.
Lead Candidate TRB-061 Advances in Atopic Dermatitis
TRex Bio’s lead candidate, TRB-061, is a TNFR2 agonist being evaluated in a Phase 1b trial for moderate-to-severe atopic dermatitis.
The company expects topline data in mid-2027, making the results an important upcoming milestone for its clinical development program.
The trial will provide further evidence on the candidate as TRex Bio evaluates its potential to address inflammatory skin disease through its immune-regulation approach.
TRB-071 Targets Inflammatory Bowel Disease
The company’s second wholly owned candidate, TRB-071, targets CD30 and is being developed for inflammatory bowel disease. The program is expected to enter Phase 1 clinical development in the first half of 2027.
Together, TRB-061 and TRB-071 extend the company’s research across inflammatory skin and gastrointestinal diseases, using different targets within its broader immune-regulation strategy.
Eli Lilly Partnership Expands the Pipeline
Eli Lilly is both an investor in TRex Bio and a discovery partner. Beyond its indicated participation in the IPO, Lilly is advancing a third candidate identified through TRex Bio’s platform into a Phase 2a trial for lupus.
This collaboration gives TRex Bio a partnership-linked development program alongside its two wholly owned candidates. The lupus program also demonstrates the platform’s application to another autoimmune disease area, although the supplied information does not disclose the financial terms of the collaboration.
Market Context & Opportunities
TRex Bio enters the public markets with a platform centered on regulatory T-cell biology and a pipeline spanning atopic dermatitis, inflammatory bowel disease and lupus. Its approach seeks to modify immune responses in inflamed tissues, potentially offering a different strategy from broad immune suppression.
The company’s relationship with Eli Lilly adds an established pharmaceutical partner to its development efforts. The upcoming TRB-061 data and planned clinical advancement of TRB-071 will be important milestones as investors evaluate the platform’s potential.
Risks & Challenges
TRex Bio remains a clinical-stage biotechnology company, and its candidates must demonstrate safety and efficacy through clinical testing. The expected mid-2027 topline results for TRB-061 will be an important test of the lead program, while TRB-071 has yet to enter its planned Phase 1 trial.
The company’s development strategy also depends on translating findings from its Deep Biology platform into successful clinical programs. As with other early-stage biotechnology businesses, trial outcomes, development timelines and future funding requirements remain important uncertainties.
Closing Paragraph
TRex Bio has raised $117 million through its Nasdaq IPO, providing capital to advance its regulatory T-cell-focused approach to autoimmune and inflammatory diseases. With TRB-061 in Phase 1b, TRB-071 expected to enter Phase 1 in 2027 and Eli Lilly advancing a partnered lupus candidate into Phase 2a, the company now faces a series of clinical milestones that will help determine the broader potential of its Deep Biology platform.
